Table 3 The predictors of overall survival and native liver survival time in hepatoblastoma children receiving SIOPEL chemotherapy
From: Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma
Native liver survival | Univariate analysis* | Multivariate analysis | ||||
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
AFP levels <1200 ng/mL (n = 21) vs. ≧ 1200 ng/mL (n = 10) after SIOPEL neo-adjuvant chemotherapy | 6.01 | 1.49–24.28 | 0.01 | 4.54 | 1.05–19.64 | 0.04 |
Female (n = 12) vs. male (n = 19) | 0.36 | 0.10–1.39 | 0.14 | - | - | - |
Age at diagnosis <=1.25 year-old (n = 16) vs. > 1.25 year-old (n = 15) | 10.06 | 1.26–80.54 | 0.03 | - | - | - |
No tumor recurrence (n = 23) vs. Tumor recurrence (n = 8) after tumor resection | 7.23 | 1.80–29.06 | 0.005 | 5.55 | 1.32–23.29 | 0.02 |
Overall survival | Univariate Analysis | Multivariate Analysis | ||||
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
AFP levels <1200 ng/mL (n = 21) vs. ≧ 1200 ng/mL (n = 10) after SIOPEL neo-adjuvant chemotherapy | 6.59 | 1.27–34.11 | 0.02 | - | - | - |
Female (n = 12) vs. male (n = 19) | 0.18 | 0.03–0.97 | 0.04 | - | - | - |
Age at diagnosis <=1.25 year-old (n = 16) vs. > 1.25 year-old (n = 15) | 7.00 | 0.84–58.19 | 0.07 | - | - | - |
No tumor recurrence (n = 23) vs. Tumor recurrence (n = 8) after tumor resection | 4.22 | 0.94–18.94 | 0.06 | - | - | - |